← Back to Search

Neurotoxin

PrabotulinumtoxinA-Xvfs for Frown Lines

Phase 2
Waitlist Available
Research Sponsored by Evolus, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up duration of effect for each subject will be based on number of days from baseline to the day that glabellar line scale severity (investigator assessment) returns to baseline value, assessed every 30 days up to 365 days.
Awards & highlights

Study Summary

This trial will compare the safety and duration of effect of two different doses of a new botulinum toxin called Jeuveau, to the standard dose of Botox Cosmetic, in adults with frown lines.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of effect for each subject will be based on number of days from baseline to the day that glabellar line scale severity (investigator assessment) returns to baseline value, assessed every 30 days up to 365 days.
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of effect for each subject will be based on number of days from baseline to the day that glabellar line scale severity (investigator assessment) returns to baseline value, assessed every 30 days up to 365 days. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Duration of Effect

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Study DrugExperimental Treatment1 Intervention
40U of PrabotulinumtoxinA-xvfs
Group II: OnabotulinumtoxinAActive Control1 Intervention
20U of OnabotulinumtoxinA
Group III: PrabotulinumtoxinA-xvfsActive Control1 Intervention
20U of PrabotulinumtoxinA-xvfs
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PrabotulinumtoxinA-Xvfs
2023
Completed Phase 2
~170

Find a Location

Who is running the clinical trial?

Evolus, Inc.Lead Sponsor
7 Previous Clinical Trials
2,366 Total Patients Enrolled
ethica Clinical Research Inc.Industry Sponsor
19 Previous Clinical Trials
1,676 Total Patients Enrolled
Rui Avelar, MDStudy DirectorEvolus, Inc.
6 Previous Clinical Trials
2,137 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor currently accepting participants?

"The clinical trial data hosted by clinicialtrials.gov indicates that this particular study, initially posted on the 30th of March 2022 and last updated 6 July 2022, is not currently enrolling patients; however, there are 9 other trials actively recruiting volunteer participants at present."

Answered by AI

Has PrabotulinumtoxinA-Xvfs been sanctioned for public use by the FDA?

"Since PrabotulinumtoxinA-Xvfs is currently in a Phase 2 trial, with data only available confirming its safety and not efficacy, we ranked it as a 2 on our scale of 1 to 3."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
2022. "Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05320393.
~51 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top